U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Pleural Biphasic Mesothelioma

MedGen UID:
1725513
•Concept ID:
C5420309
•
Neoplastic Process

Definition

Pleural biphasic mesothelioma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Pleural Biphasic Mesothelioma

Professional guidelines

PubMed

Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T
Oncology 2021;99(3):161-168. Epub 2020 Oct 14 doi: 10.1159/000510691. PMID: 33053560

Recent clinical studies

Etiology

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, Nindra U, Yip PY, Pal A, Clay T, Arulananda S, Itchins M, Pavlakis N, Kao S, Bowyer S, Chin V, Warburton L, Pires da Silva I, John T, Solomon B, Alexander M, Nagrial A
J Thorac Oncol 2024 Apr;19(4):636-642. Epub 2023 Nov 28 doi: 10.1016/j.jtho.2023.11.014. PMID: 38036250
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y, Kozuki T, Aoe K, Wada S, Harada D, Yoshida M, Sakurai J, Hotta K, Fujimoto N
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2021-003288. PMID: 34711664Free PMC Article
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T
Oncology 2021;99(3):161-168. Epub 2020 Oct 14 doi: 10.1159/000510691. PMID: 33053560
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
Ikeda T, Takemoto S, Senju H, Gyotoku H, Taniguchi H, Shimada M, Dotsu Y, Umeyama Y, Tomono H, Kitazaki T, Fukuda M, Soda H, Yamaguchi H, Fukuda M, Mukae H
Thorac Cancer 2020 Jul;11(7):1972-1978. Epub 2020 May 28 doi: 10.1111/1759-7714.13490. PMID: 32462731Free PMC Article
Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V, Wegner RE, Brooks ED, Miccio JA, Kann BH, Finley GG, Raj MS, Grover S, Mohindra P, Simone CB 2nd
Clin Lung Cancer 2019 Jul;20(4):263-269. Epub 2019 Mar 26 doi: 10.1016/j.cllc.2019.03.003. PMID: 30992187

Diagnosis

Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T
Oncology 2021;99(3):161-168. Epub 2020 Oct 14 doi: 10.1159/000510691. PMID: 33053560
Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V, Wegner RE, Brooks ED, Miccio JA, Kann BH, Finley GG, Raj MS, Grover S, Mohindra P, Simone CB 2nd
Clin Lung Cancer 2019 Jul;20(4):263-269. Epub 2019 Mar 26 doi: 10.1016/j.cllc.2019.03.003. PMID: 30992187
Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
Bahrami A, Allen TC, Cagle PT
Pathol Int 2008 Nov;58(11):730-4. doi: 10.1111/j.1440-1827.2008.02301.x. PMID: 18844940

Therapy

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, Nindra U, Yip PY, Pal A, Clay T, Arulananda S, Itchins M, Pavlakis N, Kao S, Bowyer S, Chin V, Warburton L, Pires da Silva I, John T, Solomon B, Alexander M, Nagrial A
J Thorac Oncol 2024 Apr;19(4):636-642. Epub 2023 Nov 28 doi: 10.1016/j.jtho.2023.11.014. PMID: 38036250
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y, Kozuki T, Aoe K, Wada S, Harada D, Yoshida M, Sakurai J, Hotta K, Fujimoto N
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2021-003288. PMID: 34711664Free PMC Article
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T
Oncology 2021;99(3):161-168. Epub 2020 Oct 14 doi: 10.1159/000510691. PMID: 33053560
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
Cortinovis D, Grosso F, Carlucci L, Zucali PA, Pasello G, Tiseo M, Sperandi F, Hollander L, Galli F, Torri V, Rulli E, Canova S, Maconi A, Bidoli P, Ceresoli GL, D'Incalci M; ATREUS investigators
Clin Lung Cancer 2021 Jul;22(4):361-370.e3. Epub 2020 Jul 3 doi: 10.1016/j.cllc.2020.06.028. PMID: 32732073
Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V, Wegner RE, Brooks ED, Miccio JA, Kann BH, Finley GG, Raj MS, Grover S, Mohindra P, Simone CB 2nd
Clin Lung Cancer 2019 Jul;20(4):263-269. Epub 2019 Mar 26 doi: 10.1016/j.cllc.2019.03.003. PMID: 30992187

Prognosis

CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
Inaguma S, Ueki A, Lasota J, Komura M, Sheema AN, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Schrump DS, Hassan R, Miettinen M, Takahashi S
J Pathol Clin Res 2023 May;9(3):195-207. Epub 2023 Feb 8 doi: 10.1002/cjp2.310. PMID: 36754859Free PMC Article
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
Cortinovis D, Grosso F, Carlucci L, Zucali PA, Pasello G, Tiseo M, Sperandi F, Hollander L, Galli F, Torri V, Rulli E, Canova S, Maconi A, Bidoli P, Ceresoli GL, D'Incalci M; ATREUS investigators
Clin Lung Cancer 2021 Jul;22(4):361-370.e3. Epub 2020 Jul 3 doi: 10.1016/j.cllc.2020.06.028. PMID: 32732073
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
Ikeda T, Takemoto S, Senju H, Gyotoku H, Taniguchi H, Shimada M, Dotsu Y, Umeyama Y, Tomono H, Kitazaki T, Fukuda M, Soda H, Yamaguchi H, Fukuda M, Mukae H
Thorac Cancer 2020 Jul;11(7):1972-1978. Epub 2020 May 28 doi: 10.1111/1759-7714.13490. PMID: 32462731Free PMC Article
Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V, Wegner RE, Brooks ED, Miccio JA, Kann BH, Finley GG, Raj MS, Grover S, Mohindra P, Simone CB 2nd
Clin Lung Cancer 2019 Jul;20(4):263-269. Epub 2019 Mar 26 doi: 10.1016/j.cllc.2019.03.003. PMID: 30992187
Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
Bahrami A, Allen TC, Cagle PT
Pathol Int 2008 Nov;58(11):730-4. doi: 10.1111/j.1440-1827.2008.02301.x. PMID: 18844940

Clinical prediction guides

CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
Inaguma S, Ueki A, Lasota J, Komura M, Sheema AN, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Schrump DS, Hassan R, Miettinen M, Takahashi S
J Pathol Clin Res 2023 May;9(3):195-207. Epub 2023 Feb 8 doi: 10.1002/cjp2.310. PMID: 36754859Free PMC Article
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y, Kozuki T, Aoe K, Wada S, Harada D, Yoshida M, Sakurai J, Hotta K, Fujimoto N
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2021-003288. PMID: 34711664Free PMC Article
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
Ikeda T, Takemoto S, Senju H, Gyotoku H, Taniguchi H, Shimada M, Dotsu Y, Umeyama Y, Tomono H, Kitazaki T, Fukuda M, Soda H, Yamaguchi H, Fukuda M, Mukae H
Thorac Cancer 2020 Jul;11(7):1972-1978. Epub 2020 May 28 doi: 10.1111/1759-7714.13490. PMID: 32462731Free PMC Article
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K
J Clin Oncol 2019 Oct 1;37(28):2537-2547. Epub 2019 Aug 6 doi: 10.1200/JCO.19.00269. PMID: 31386610Free PMC Article
Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V, Wegner RE, Brooks ED, Miccio JA, Kann BH, Finley GG, Raj MS, Grover S, Mohindra P, Simone CB 2nd
Clin Lung Cancer 2019 Jul;20(4):263-269. Epub 2019 Mar 26 doi: 10.1016/j.cllc.2019.03.003. PMID: 30992187

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...